Medigen Vaccine Biologics Corporation

6547

TW0006547003

Pharmaceuticals

End-of-day quote Taipei Exchange Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
51.3 ^TWD	-1.35%		+5.77%	-26.82%

Mar. 15	Medigen Vaccine Biologics Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Medigen Vaccine Biologics Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI

Medigen Vaccine Biologics Corporation Appoints Jade Yang as Chief Financial Officer

February 08, 2022 at 02:58 am EST

Medigen Vaccine Biologics Corporation announced the appointment of Jade Yang as Chief Financial Officer effective January 3, 2022.

Latest news about Medigen Vaccine Biologics Corporation

Medigen Vaccine Biologics Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 15	CI
Medigen Vaccine Biologics Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Medigen Vaccine Biologics Corporation Provides License Covid-19 Vaccine to WHO C-TAP and UN Medicines Patent Pool	23-08-29	CI
Medigen Vaccine Biologics Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Medigen Vaccine Biologics Corporation Withdraws Covid-19 Vaccine Provisional Application and Update with Three-Dose Data for Further Review	23-07-21	CI
Medigen Vaccine Biologics Corporation Approves the Election of Ming-Yi ,Wu as Independent Director and Member of Audit and Remuneration Committees	23-06-29	CI
Medigen Vaccine Biologics Corporation Files New Drug Application of MVC EV71 Vaccine to Drug Administration of Vietnam	23-05-24	CI
Medigen Vaccine Biologics Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Medigen Vaccine Biologics Corporation Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-15	CI
Medigen Vaccine Biologics Corporation Announces Board Changes	23-03-08	CI
Medigen Vaccine Biologics Corporation Announces the Resignation of Chang, Ming-Cheng as Independent Director	23-03-08	CI
Medigen Vaccine Biologics Corporation Receives the NDA Approval Letter of Mvcquadrivalent Influenza Vaccine from Taiwan Food and Drug Administration	23-03-08	CI
Medigen Vaccine Biologics Corporation Announces Results of MVC COVID-19 Vaccine Phase 3 Clinical Trial in Thailand	22-12-05	CI
Medigen Vaccine Biologics Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
Medigen Vaccine Biologics Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-11	CI
Taiwan's Medigen Vaccine Seeks Regulatory Approval for COVID Vaccine in Australia	22-06-07	MT
MVC File Provisional Approval Application of COVID-19 Vaccine to Therapeutic Goods Administration	22-06-06	CI
Medigen Vaccine Biologics Corporation Announces Update on Clinical Development on MVC Covid-19 Vaccine	22-05-13	CI
Medigen Vaccine Biologics Corporation Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-12	CI
Taiwan approves second COVID booster dose, infections yet to peak	22-04-21	RE
Medigen Vaccine Biologics Corporation Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-11	CI
Bluewillow Biologics and Medigen Vaccine Biologics Announce Positive Results for Intranasal Covid-19 Booster Candidate in Pre-Clinical Studies	22-03-02	CI
Medigen Vaccine Biologics Corporation Files New Drug Application of MVC Quadrivalent Influenza Vaccine to Taiwan Food and Drug Administration	22-02-08	CI
Medigen Vaccine Biologics Corporation Appoints Jade Yang as Chief Financial Officer	22-02-08	CI
Taiwan tries hand at COVID diplomacy again with Somaliland vaccine gift	22-01-31	RE

Chart Medigen Vaccine Biologics Corporation

Duration

Period

Chart Medigen Vaccine Biologics Corporation

More charts

Medigen Vaccine Biologics Corporation is a Taiwan-based company principally engaged in the development and manufacturing of vaccines and biological agents. The Company is engaged in the development of cutting edge technologies for cell-based human vaccines production. For vaccine development, the Company has established the manufacturing process for H1N1 and H5N1. Further, it also conducts clinical trials to confirm safety and efficacy of produced vaccines. In addition, the Company is also engaged in biological agents business.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
MEDIGEN VACCINE BIOLOGICS CORPORATION	-26.82%	517M
CSL LIMITED	-4.66%	86.13B
SAMSUNG BIOLOGICS CO.,LTD.	+1.32%	39.82B
BIOGEN INC.	-19.27%	30.42B
UCB	+57.86%	25.23B
INCYTE CORPORATION	-17.69%	11.6B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-43.00%	11.51B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-9.14%	11.95B
SWEDISH ORPHAN BIOVITRUM AB	+5.24%	8.71B
INNOVENT BIOLOGICS, INC.	-8.42%	8.12B

Biopharmaceuticals